MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
49.49
+0.74
+1.51%
Opening 10:25 12/18 EST
OPEN
48.87
PREV CLOSE
48.75
HIGH
49.66
LOW
48.63
VOLUME
187.08K
TURNOVER
--
52 WEEK HIGH
57.65
52 WEEK LOW
29.16
MARKET CAP
2.84B
P/E (TTM)
-145.2025
1D
5D
1M
3M
1Y
5Y
1D
Supernus Pharmaceuticals: Strategic Growth, Clinical Advances, and Strong Financial Synergies Drive Buy Rating
TipRanks · 1d ago
Supernus management to meet virtually with Cantor Fitzgerald
TipRanks · 1d ago
Weekly Report: what happened at SUPN last week (1208-1212)?
Weekly Report · 3d ago
1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down
Barchart · 3d ago
3 Stocks Under $50 That Concern Us
Barchart · 6d ago
Weekly Report: what happened at SUPN last week (1201-1205)?
Weekly Report · 12/08 09:45
3 Unprofitable Stocks We Find Risky
Barchart · 12/04 04:56
Supernus Pharmaceuticals to Present at Bank of America Securities CNS Therapeutics Virtual Conference
Reuters · 12/03 21:05
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.